Vaprisol advisory committee cancelled
Executive Summary
The Sept. 9 review of Yamanouchi's Vaprisol (conivaptan) by FDA's Endocrinologic & Metabolic Drugs Advisory Committee has been cancelled. The hyponatremia (water poisoning) treatment's user fee date is in November; the committee's next tentative meeting dates are Dec. 13 & 14...